{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:24:20Z","timestamp":1793049860377,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-022-01031-6","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:03:39Z","timestamp":1666785819000},"page":"34-44","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2303-5401","authenticated-orcid":false,"given":"Tomohiro","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mizobuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taihei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Makuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"7","key":"1031_CR1","first-page":"1","volume":"2011","author":"Group KDIGOKC-MUW","year":"2017","unstructured":"Group KDIGOKC-MUW (2017) KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2011(7):1\u201359","journal-title":"Kidney Int Suppl"},{"key":"1031_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000209249","volume":"27","author":"P Messa","year":"2009","unstructured":"Messa P, Cerutti R, Brezzi B, Alfieri C, Cozzolino M (2009) Calcium and phosphate control by dialysis treatments. Blood Purif 27:360\u2013368","journal-title":"Blood Purif"},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00774-020-01149-3","volume":"38","author":"I Kanazawa","year":"2020","unstructured":"Kanazawa I, Inaba M, Inoue D, Uenishi K, Saito M, Shiraki M, Suzuki A, Takeuchi Y, Hagino H, Fujiwara S, Sugimoto T (2020) Executive summary of clinical practice guide on fracture risk in lifestyle diseases. J Bone Miner Metab 38:746\u2013758","journal-title":"J Bone Miner Metab"},{"key":"1031_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ki.2013.279","volume":"85","author":"F Tentori","year":"2014","unstructured":"Tentori F, McCullough K, Kilpatrick RD, Bradbury BD, Robinson BM, Kerr PG, Pisoni RL (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85:166\u2013173","journal-title":"Kidney Int"},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1210\/en.2007-0270","volume":"148","author":"R Baron","year":"2007","unstructured":"Baron R, Rawadi G (2007) Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148:2635\u20132643","journal-title":"Endocrinology"},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"1031_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25:948\u2013959","journal-title":"J Bone Miner Res"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/jbmr.182","volume":"25","author":"X Li","year":"2010","unstructured":"Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25:2647\u20132656","journal-title":"J Bone Miner Res"},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1031_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1031_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2050","author":"CP Hsu","year":"2022","unstructured":"Hsu CP, Maddox J, Block G, Bartley Y, Yu Z (2022) Influence of renal function on pharmacokinetics, pharmacodynamics, and safety of a single dose of romosozumab. J Clin Pharmacol. https:\/\/doi.org\/10.1002\/jcph.2050","journal-title":"J Clin Pharmacol"},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39:1082\u20131090","journal-title":"J Bone Miner Metab"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.17219\/acem\/68739","volume":"26","author":"B Pietrzyk","year":"2017","unstructured":"Pietrzyk B, Smertka M, Chudek J (2017) Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv Clin Exp Med 26:1283\u20131291","journal-title":"Adv Clin Exp Med"},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ndt\/gfy129","volume":"34","author":"VM Brandenburg","year":"2019","unstructured":"Brandenburg VM, Verhulst A, Babler A, D\u2019Haese PC, Evenepoel P, Kaesler N (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34:408\u2013414","journal-title":"Nephrol Dial Transplant"},{"key":"1031_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s40620-017-0410-1","volume":"30","author":"L Tartaglione","year":"2017","unstructured":"Tartaglione L, Pasquali M, Rotondi S, Muci ML, Covic A, Mazzaferro S (2017) Positioning novel biologicals in CKD-mineral and bone disorders. J Nephrol 30:689\u2013699","journal-title":"J Nephrol"},{"key":"1031_CR16","doi-asserted-by":"publisher","first-page":"3485785","DOI":"10.1155\/2017\/3485785","volume":"2017","author":"Y Iwasaki","year":"2017","unstructured":"Iwasaki Y, Kazama JJ, Fukagawa M (2017) Molecular abnormalities underlying bone fragility in chronic kidney disease. Biomed Res Int 2017:3485785","journal-title":"Biomed Res Int"},{"key":"1031_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"1031_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34:419\u2013428","journal-title":"J Bone Miner Res"},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471\u20131479","journal-title":"J Bone Miner Res"},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","volume":"29","author":"C Thongprayoon","year":"2018","unstructured":"Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, Sharma K, Wijarnpreecha K, Ungprasert P, Gonzalez Suarez ML, Cheungpasitporn W (2018) Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int 29:1737\u20131745","journal-title":"Osteoporos Int"},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40620-016-0334-1","volume":"30","author":"F Festuccia","year":"2017","unstructured":"Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S, Sciacchitano S, Punzo G, Men\u00e8 P (2017) Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30:271\u2013279","journal-title":"J Nephrol"},{"key":"1031_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06386-y","author":"K Ebina","year":"2022","unstructured":"Ebina K, Etani Y, Tsuboi H, Nagayama Y, Kashii M, Miyama A, Kunugiza Y, Hirao M, Okamura G, Noguchi T, Takami K, Goshima A, Miura T, Fukuda Y, Kurihara T, Okada S, Nakata K (2022) Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-022-06386-y","journal-title":"Osteoporos Int"},{"key":"1031_CR23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Kato Y (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32:1999\u20132009","journal-title":"Osteoporos Int"},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2013executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T, Group C-MGW, Japanese Society for Dialysis T","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T, Group C-MGW, Japanese Society for Dialysis T (2013) Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17:247\u2013288","journal-title":"Ther Apher Dial"},{"key":"1031_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","volume":"498","author":"Y Nishizawa","year":"2019","unstructured":"Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M, Takada J, Chaki O, Hagino H, Fukunaga M, Fujiwara S, Miki T, Yoshimura N, Ohta H (2019) Executive summary of the Japan osteoporosis society guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2018 edition). Clin Chim Acta 498:101\u2013107","journal-title":"Clin Chim Acta"},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, D\u2019Haese PC, Dr\u00fceke TB, Du H, Manley T, Rojas E, Moe SM (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD Treated by Dialysis. Am J Kidney Dis 67:559\u2013566","journal-title":"Am J Kidney Dis"},{"key":"1031_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00223-008-9127-4","volume":"82","author":"K Shidara","year":"2008","unstructured":"Shidara K, Inaba M, Okuno S, Yamada S, Kumeda Y, Imanishi Y, Yamakawa T, Ishimura E, Nishizawa Y (2008) Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82:278\u2013287","journal-title":"Calcif Tissue Int"},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00198-018-4492-y","volume":"29","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hirao M, Hashimoto J, Matsuoka H, Iwahashi T, Chijimatsu R, Etani Y, Okamura G, Miyama A, Yoshikawa H (2018) Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-na\u00efve rheumatoid arthritis. Osteoporos Int 29:1627\u20131636","journal-title":"Osteoporos Int"},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1385\/JCD:8:4:371","volume":"8","author":"S Baim","year":"2005","unstructured":"Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr, Lentle BC (2005) Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 8:371\u2013378","journal-title":"J Clin Densitom"},{"key":"1031_CR31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jacc.2005.12.030","volume":"47","author":"MJ Budoff","year":"2006","unstructured":"Budoff MJ, Achenbach S, Fayad Z, Berman DS, Poon M, Taylor AJ, Uretsky BF, Williams KA (2006) Task Force 12: training in advanced cardiovascular imaging (computed tomography): endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Atherosclerosis Imaging and Prevention, and Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 47:915\u2013920","journal-title":"J Am Coll Cardiol"},{"key":"1031_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0735-1097(90)90282-T","volume":"15","author":"AS Agatston","year":"1990","unstructured":"Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827\u2013832","journal-title":"J Am Coll Cardiol"},{"key":"1031_CR33","doi-asserted-by":"crossref","unstructured":"Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z (2022) Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res","DOI":"10.1002\/jbmr.4563"},{"key":"1031_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A, Nakata K (2020) Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574","journal-title":"Bone"},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00774-021-01226-1","volume":"39","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Arita K, Murota E, Hiratsuka S, Fujita R, Ishizu H, Asano T, Takahashi D, Takahata M, Iwasaki N (2021) Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients. J Bone Miner Metab 39:868\u2013875","journal-title":"J Bone Miner Metab"},{"key":"1031_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00198-020-05639-y","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Kato Y, Nishi H, Terayama Y, Okazaki K (2021) Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study. Osteoporos Int 32:653\u2013661","journal-title":"Osteoporos Int"},{"key":"1031_CR37","first-page":"67","volume":"17","author":"L Ha","year":"2020","unstructured":"Ha L, Shi JB, Yu HY, Yang K, Wang HN, Wang FF, Han JL (2020) Association between serum cartilage oligomeric matrix protein and coronary artery calcification in maintenance hemodialysis patients. J Geriatr Cardiol 17:67\u201373","journal-title":"J Geriatr Cardiol"},{"key":"1031_CR38","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.kint.2016.09.024","volume":"91","author":"M Vervloet","year":"2017","unstructured":"Vervloet M, Cozzolino M (2017) Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int 91:808\u2013817","journal-title":"Kidney Int"},{"key":"1031_CR39","doi-asserted-by":"publisher","first-page":"F663","DOI":"10.1152\/ajprenal.00189.2016","volume":"311","author":"K Zhang","year":"2016","unstructured":"Zhang K, Gao J, Chen J, Liu X, Cai Q, Liu P, Huang H (2016) MICS, an easily ignored contributor to arterial calcification in CKD patients. Am J Physiol Renal Physiol 311:F663-f670","journal-title":"Am J Physiol Renal Physiol"},{"key":"1031_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00198-015-3233-8","volume":"27","author":"L Viaene","year":"2016","unstructured":"Viaene L, Behets GJ, Heye S, Claes K, Monbaliu D, Pirenne J, D\u2019Haese PC, Evenepoel P (2016) Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos Int 27:489\u2013497","journal-title":"Osteoporos Int"},{"key":"1031_CR41","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/ndt\/gfu301","volume":"30","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30:288\u2013293","journal-title":"Nephrol Dial Transplant"},{"key":"1031_CR42","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s11255-018-1795-z","volume":"50","author":"L Gong","year":"2018","unstructured":"Gong L, Zheng D, Yuan J, Cao L, Ni Z, Fang W (2018) Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients. Int Urol Nephrol 50:955\u2013961","journal-title":"Int Urol Nephrol"},{"key":"1031_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00198-017-4228-4","volume":"29","author":"HH Malluche","year":"2018","unstructured":"Malluche HH, Monier-Faugere MC, Blomquist G, Davenport DL (2018) Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors. Osteoporos Int 29:125\u2013134","journal-title":"Osteoporos Int"},{"key":"1031_CR44","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s00198-021-05975-7","volume":"32","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, Prieto-Alhambra D, Torres PU, Cannata-Andia J (2021) Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int 32:2397\u20132405","journal-title":"Osteoporos Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-022-01031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-022-01031-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-022-01031-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:02:43Z","timestamp":1672858963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-022-01031-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1007\/s00223-022-01031-6","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"14 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tomohiro Saito, Masahide Mizobuchi, Tadashi Kato, Taihei Suzuki, Yasuro Fujiwara, Naoaki Kanamori, Mikio Makuuchi, and Hirokazu Honda declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the ethical committee of the Showa University Hospital (No. 2896) and registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR ID: UMIN000039889). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.\u00a0All participants gave written informed consent.\u00a0No animal studies were performed in the course of these experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}